

SUPPLEMENTAL MATERIAL

Table 1. The baseline differences characteristics between with and without aortic-related adverse event in the study population (n=109).

Characteristic	With aortic-related adverse event (n=34)	Without aortic-related adverse event (n=75)	<i>P</i> value
Demographic and clinical data			
Age, y	63.50±9.64	65.99±10.25	0.235
Men, n (%)	28 (82.35)	59 (78.67)	0.657
BMI	25.03±3.66	24.93±3.16	0.883
Systemic hypertension, n (%)	28 (82.35)	60 (80.00)	0.773
Smoking, n (%)	28 (82.35)	50 (67.57)	0.111
Hyperlipidemia, n (%)	13 (38.24)	23 (30.67)	0.436
Diabetes, n (%)	5 (14.71)	5 (6.67)	0.280
Coronary heart disease, n (%)	10 (29.41)	27 (36.00)	0.501
Imaging			
Mean number of penetrating atherosclerotic ulcers	1.06±0.34	1.19±0.43	0.099
Aortic arch, n (%)	8 (23.53)	25 (33.33)	0.302
Descending thoracic aorta, n (%)	25 (73.53)	47 (62.67)	0.267
Abdominal aorta, n (%)	1 (2.94)	3 (4.00)	1.000
Mean ulcer diameter, mm	13.27±5.18	10.42±5.35	0.010
Mean ulcer depth, mm	9.91±5.13	7.42±3.99	0.007
Maximum ascending aorta	42.42±4.71	43.37±4.90	0.345

diameter, mm

Maximum descending aorta	30.53±7.09	30.29±4.87	0.859
--------------------------	------------	------------	-------

diameter, mm

Pleural effusion, n (%)	11 (32.35)	22 (29.33)	0.751
-------------------------	------------	------------	-------

Pericardial effusion, n (%)	0 (0.00)	1 (1.33)	1.000
-----------------------------	----------	----------	-------

Medical

Antiplatelet agents, n (%)	2 (5.88)	3 (4.00)	0.646
----------------------------	----------	----------	-------

Beta-blockers, n (%)	3 (8.82)	5 (6.67)	0.703
----------------------	----------	----------	-------

Calcium antagonists, n (%)	10 (29.41)	25 (33.33)	0.685
----------------------------	------------	------------	-------

ACE inhibitors, n (%)	0 (0.00)	5 (6.67)	0.322
-----------------------	----------	----------	-------

ARB inhibitors, n (%)	5 (14.71)	11 (14.67)	1.000
-----------------------	-----------	------------	-------

Nitrates, n (%)	1 (2.94)	3 (4.00)	1.000
-----------------	----------	----------	-------

Statins, n (%)	1 (2.94)	4 (5.33)	1.000
----------------	----------	----------	-------

Systolic BP, mmHg	151.03±30.55	149.64±20.90	0.783
-------------------	--------------	--------------	-------

Diastolic BP, mmHg	86.38±14.61	85.45±12.66	0.736
--------------------	-------------	-------------	-------

Heart rate, BPM	77.29±9.57	79.79±10.81	0.251
-----------------	------------	-------------	-------

Laboratory examinations

CKMB, ng/ml	11.00 (8.75, 14.00)	12.00 (8.00, 16.00)	0.593
-------------	---------------------	---------------------	-------

TNT exception, n (%)	9 (26.47)	24 (32.00)	0.560
----------------------	-----------	------------	-------

ALT, U/L	18.40 (12.93, 27.18)	15.63 (11.60, 22.00)	0.100
----------	----------------------	----------------------	-------

AST, U/L	19.58 (15.86, 24.01)	17.84 (14.31, 24.39)	0.482
----------	----------------------	----------------------	-------

WBC, 10 ⁹ /L	10.67±3.43	9.66±2.29	0.121
-------------------------	------------	-----------	-------

PLT, 10 ⁹ /L	237.68±135.32	219.31±73.24	0.461
HG, g/L	134.35±15.18	132.52±18.42	0.613
BUN, mmol/L	6.54 (4.99, 9.59)	6.33 (4.96, 9.05)	0.537
CR, μmol/L	78.80 (70.25, 101.30)	84.44 (68.20, 103.00)	0.736
C-reactive protein, mg/dL	54.02 (26.83, 88.33)	44.60 (15.90, 55.87)	0.067
D-dimer, ng/ml	1.33 (0.68, 3.18)	1.61 (0.80, 2.74)	0.971

BMI, Body Mass Index; ACE, Angiotensin-converting Enzyme; ARB, Angiotensin Receptor Blocker; BP, Blood Pressure; CKMB, Creatine Phosphokinase-myocardial Band; TNT, Troponin-T; BNP, Brain Natriuretic Peptide; ALT, Alanine Aminotransferase; AST, Aspartate aminotransferase; WBC, White Blood Cell; PLT, Platelet Count; HG, Hemoglobin; CR, Creatinine. Data are expressed as mean±SD, medians (25th percentiles, 75th percentiles), or number (percentage).

Figure S1. Statistical analysis protocol.

